Softwr

Healthcare · head to head

Ibex Medical Analytics vs PathAI

Ibex Medical Analytics logo

Ibex Medical Analytics

Healthcare

Cancer detection AI for breast, prostate and gastric pathology deployed in routine clinical service, not just pilots

From
On request
Rated
-
Full reviewWebsite
PathAI logo

PathAI

Healthcare

Digital pathology image management with an FDA cleared platform for primary diagnosis

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Ibex Medical Analytics the European IVDR indication is broader than the United States position, where some applications operate under laboratory developed test arrangements rather than FDA authorisation, which determines whether AI output can influence a signed report.; PathAI aISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • They diverge on capability: Ibex Medical Analytics covers Ibex Breast Suite, PathAI covers AISight image management.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Ibex Medical Analytics and PathAI actually diverge.

Attributes where Ibex Medical Analytics and PathAI differ
AttributeIbex Medical AnalyticsPathAI
PlatformsWeb, Cloud, On-premiseWeb

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Ibex Medical Analytics

  • Ibex Breast Suite
  • Ibex Prostate
  • Ibex Gastric
  • Second read safety net
  • Prescreening triage
  • Heatmap localisation
  • Quality reporting
  • Scanner-agnostic ingestion

Only in PathAI

  • AISight image management
  • AISight Dx
  • Scanner interoperability
  • Case and worklist management
  • AI algorithm deployment
  • Biopharmaceutical research tooling
  • LIS integration

What people use each for

The jobs each tool is most often brought in to do.

Ibex Medical Analytics

  • A histopathology department that cannot recruit and wants an automated safety net on every prostate and breast biopsy before sign outnot PathAI
  • A private laboratory group standardising Gleason grading across pathologists with known interobserver variabilitynot PathAI
  • A service digitising histopathology that needs a clinical governance argument to justify the scanning programme to its boardnot PathAI
  • A gastrointestinal service wanting Helicobacter pylori detection automated so pathologists spend their time on the neoplastic casesnot PathAI

PathAI

  • An academic medical centre going digital for primary diagnosis that needs the FDA cleared AISight Dx configuration rather than the research labelled versionnot Ibex Medical Analytics
  • A reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any locationnot Ibex Medical Analytics
  • A pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readersnot Ibex Medical Analytics
  • A laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewernot Ibex Medical Analytics

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Ibex Medical Analytics

  • The European IVDR indication is broader than the United States position, where some applications operate under laboratory developed test arrangements rather than FDA authorisation, which determines whether AI output can influence a signed report.
  • It requires a fully digitised histopathology workflow, and slide scanning, storage and validation typically cost several times the algorithm licence.
  • Running it as a second read safety net adds a discrepancy resolution workload that departments consistently underestimate, and someone senior has to adjudicate every flag.
  • Coverage is limited to breast, prostate and gastric, so a general histopathology department still reads the majority of its case mix without any AI support.
  • Pricing is per case and unpublished, so cost scales directly with biopsy volume and does not flatten as the department grows.

PathAI

  • AISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • The software licence is usually the smallest line in a digital pathology project, behind scanners, storage and network capacity, so a business case built around the software cost understates the real investment by a wide margin.
  • Whole slide images are very large, so a laboratory that does not model storage growth and retention policy from the start faces storage costs that grow faster than case volume and dominate the renewal.
  • Clinical validation is required per subspecialty rather than once for the platform, which means dermatopathology, gastrointestinal and breast each need their own concordance study and pathologist time before go live.
  • PathAI competes against pathology incumbents that also sell the scanners, and a laboratory buying an independent image management layer takes on the integration risk between scanner vendor and software vendor itself.

Pricing, plan by plan

Ibex Medical Analytics

On request
  • Ibex clinical applications$undefined/year
    • Priced per case analysed under an annual agreement
    • Breast, prostate and gastric licensed as separate suites
    • Regulatory indication differs between Europe and the United States

PathAI

On request
  • AISight$undefined/year
    • Priced by annual slide or case volume and by pathologist seats
    • AISight Dx, the clinically cleared configuration, quoted separately from research use AISight
    • Image storage priced by capacity and retention policy

Which should you pick?

Choose Ibex Medical Analytics if

  • You need ibex breast suite.
  • You work on Web, Cloud, On-premise.
  • You also want ibex prostate.
Ibex Medical Analytics review

Choose PathAI if

  • You need aisight image management.
  • You also want aisight dx.
PathAI review

Questions people ask

Is Ibex Medical Analytics or PathAI better?
Neither clearly leads. Ibex Medical Analytics starts at On request and PathAI at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Ibex Medical Analytics or PathAI?
Ibex Medical Analytics starts at On request and PathAI at On request.
Does Ibex Medical Analytics or PathAI run on more platforms?
Ibex Medical Analytics runs on Web, Cloud, On-premise. PathAI runs on Web.
What is Ibex Medical Analytics best used for?
Ibex Medical Analytics is most often used for a histopathology department that cannot recruit and wants an automated safety net on every prostate and breast biopsy before sign out, a private laboratory group standardising gleason grading across pathologists with known interobserver variability, a service digitising histopathology that needs a clinical governance argument to justify the scanning programme to its board, a gastrointestinal service wanting helicobacter pylori detection automated so pathologists spend their time on the neoplastic cases. Of those, a histopathology department that cannot recruit and wants an automated safety net on every prostate and breast biopsy before sign out and a private laboratory group standardising gleason grading across pathologists with known interobserver variability are not what PathAI is typically brought in for.
What can Ibex Medical Analytics do that PathAI cannot?
Ibex Medical Analytics covers Ibex Breast Suite, Ibex Prostate, Ibex Gastric, Second read safety net. PathAI covers AISight image management, AISight Dx, Scanner interoperability, Case and worklist management.

Answered from the vendors’ own pages

Ibex Medical Analytics: Is Ibex FDA cleared?

The regulatory position differs by product and market. In Europe the products carry CE marking under IVDR for defined diagnostic indications; in the United States some applications are used under laboratory developed test arrangements. Confirm the exact status for the specific application and market before assuming it can influence a signed report.

PathAI: What is the difference between AISight and AISight Dx?

AISight is for research use only and not for clinical diagnostic use. AISight Dx received FDA 510(k) clearance in June 2025 for primary diagnosis and is CE-IVD marked in the EEA, UK and Switzerland. Only the Dx configuration can be used to sign out cases.

Ibex Medical Analytics: Second read or prescreening?

Both are supported. Second read as a safety net is the more common clinical governance justification; prescreening is the efficiency case.

PathAI: Can we use our existing scanners?

Yes. AISight is designed to ingest images from multiple whole slide scanner vendors, which is one of the main reasons laboratories choose an independent image management layer.

Ibex Medical Analytics: Does it need a particular scanner?

It ingests from the major whole slide scanner vendors rather than requiring a single fleet, which is a practical advantage over vendors tied to one scanner.

PathAI: Do the AI algorithms carry the same clearance as the platform?

No. The platform clearance covers image management for primary diagnosis. Individual algorithms have their own labelling, and many are research use only. Check each one separately.

Ibex Medical Analytics: What tissue types are covered?

Breast, prostate and gastric. Everything else in the case mix is unsupported.

PathAI: Is pricing published?

No. It is quoted by slide or case volume, pathologist seats and storage, with the clinically cleared configuration priced separately.

Share

Related pages

More on Ibex Medical Analytics

More on PathAI

Keep looking

Other head to heads